Table. Characteristics of participants in a study of immune response against variants of concern in dialysis patients 4 months after SARS-CoV-2 mRNA vaccination*.
| Characteristic | Nondialysis control group | Hemodialysis group | p value for difference between groups |
|---|---|---|---|
| No. (%) patients |
23 (100) |
76 (100) |
NA |
| Median age, y (IQR) |
55 (14) |
70.5 (18.25) |
2.78 × 10−9 |
| Sex | 1.01 × 10−2† | ||
| M | 6 (26.09) | 43 (56.58) | |
| F |
17 (73.91) |
33 (43.42) |
|
| Median days since start of hemodialysis (IQR) |
NA |
1,337 (1,686.5) |
NA |
| Using immunosuppressive medication |
0 |
10 (13.16) |
6.77 × 10−2 |
| Underlying condition | |||
| Obesity, BMI >30‡ | 4 (17.39) | 16 (21.05) | 8.68 × 10−1 |
| Diabetes mellitus | 0 | 19 (25) | 7.30 × 10−3 |
| Cardiovascular disease | 0 | 35 (46.05) | 2.93 × 10−5 |
*Values are no. (%) except as indicated. Percentages are for total group. BMI, body mass index; IQR, interquartile range; NA, not applicable; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †p value reflects difference in male-to-female ratios between the two groups, not differences explicitly for either male or female persons. ‡BMI for 1 person was not known.